Can Erdafitinib cure bladder cancer?

Erdafitinib (Erdafitinib) can be a targeted treatment for patients with advanced or metastatic bladder cancer with specific gene mutations. It inhibits specific signaling pathways to prevent the growth and spread of cancer cells. Although erdafitinib can play a positive therapeutic role in some patients with bladder cancer, it does not guarantee a complete cure from bladder cancer. Treatment results will vary based on factors such as individual circumstances, tumor characteristics, and duration of treatment.

In a clinical study of erdafitinib, a total of 99 patients in the selected regimen group received a median of 5 cycles of erdafitinib. Among these patients, 43% had received at least two prior courses of treatment, 79% had visceral metastases, and 53% had creatinine clearance less than 60 ml per minute. The confirmed response rate of erdafitinibtreatment was 40% (3% complete response, 37% partial response). Among 22 patients who had previously received immunotherapy, the confirmed response rate was 59%. The median progression-free survival was 5.5 months and the median overall survival was 13.8 months. Grade 3 or higher treatment-related adverse events were reported in 46% of patients and were primarily managed by dose adjustments; 13% of patients discontinued treatment due to adverse events. There were no treatment-related deaths.

The original version of erdafitinib has not yet been launched in China, so it cannot be covered by medical insurance. The original version of erdafitinib currently sold in Hong Kong may cost more than 20,000 yuan per box of specifications 4mg*14 tablets (the price may fluctuate due to exchange rates). Cheaper erdafitinib generic drugs produced by other pharmaceutical factories are also sold overseas. The pharmaceutical ingredients are basically the same as those of the original drug. For example, the price of 4mg*60 tablets produced by a Bangladeshi pharmaceutical factory may be more than 3,000 yuan per box (the price may fluctuate due to exchange rates).